Despite advancements, Primary Graft Dysfunction (PGD) mortality and a lack of donor organs both continue to hinder lung transplantation. We looked at cytokine adsorption as a treatment for Acute Respiratory Distress Syndrome (ARDS) donor lungs since ARDS restricts the use of donor lungs. Using lipopolysaccharide, it caused mild to moderate ARDS in 16 donor pigs. Then, during Ex Vivo Lung Perfusion (EVLP) and/or post-transplantation utilizing extracorporeal hemoperfusion, the treatment of the lungs was performed with or without cytokine adsorption. The medication dramatically reduced post-transplant immune cell counts as well as cytokine levels during EVLP. The incidence of PGD was dramatically decreased in treated mice, and histology showed fewer symptoms of lung damage during both treatment periods. Overall, lung transplantation with cytokine adsorption was successful in restoring lung function and lowering PGD.
